Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Faster insulin aspart shows real-world efficacy for T1D

Tristan Manalac
25 Sep 2020

For patients with type 1 diabetes (T1D), switching to faster insulin aspart may improve glycated haemoglobin (HbA1c), time-in-range (TIR), and time in hyperglycaemia, without posing serious hypoglycaemia risks, according to a new study.

“Most of the clinical data on faster aspart are from the controlled ‘onset’ treat-to-target clinical trials; there is limited real-world evidence of the impact of faster aspart,” the researchers said. The present study thus sought to remedy that, using intermittent-scanning continuous glucose monitoring (iscCGM) to illustrate the impact of the intervention.

In total, 243 T1D patients (mean age, 49.9±16.6 years; 55.6 percent male) were enrolled in the full analysis set, from which subsets were drawn for efficacy analysis and safety analysis, with or without available iscCGM data.

Patients who were on faster aspart saw a drop in HbA1c, from 8.1 percent at baseline to 7.9 percent after 24 weeks of medication. The resulting difference value was statistically significant (–0.19 percent, 95 percent confidence interval [CI], –0.27 to –0.10; p<0.0001). The 12-week change in HbA1c also represented a significant drop from baseline (–0.15 percent, 95 percent CI, –0.24 to –0.07; p=0.001). [Diabetes Technol Ther 2020;doi:10.1089/dia.2020.0360]

For the efficacy analysis, 92 patients had available data from the iscCGM devices. These patients showed a significant 24-week drop in postprandial glucose (–0.8±2.4 mmol/L; p=0.002), fasting preprandial glucose (–0.8±2.4 mmol/L; p=0.005), and estimated HbA1c (–0.2±0.8 percent; p=0.035).

Moreover, the devices recorded a significant increase in the average minutes per day spent in the target range by 46.1 minutes (p=0.009). This was accompanied by a drop in the time spent in hyperglycaemia, as defined by a >10 mmol/L threshold, by 43.5 minutes (p=0.024). When the threshold for hyperglycaemia was raised to >13.9 mmol/L, the change in the time spent decreased slightly but remained significant (–35.6 minutes; p=0.015).

In comparison, the time spent in hypoglycaemia was virtually unchanged as compared with baseline values. The same was true for the number of episodes of hypoglycaemia or of very low glucose.

In terms of safety, the researchers reported six serious adverse reactions (SARs), five of which were nonfatal and occurred in four patients; one SAR episode was fatal and happened after a patient engaged in physical activities and experienced very low blood sugar. All nonfatal SARs were hospitalizations due to ketoacidosis.

“The key strength of the study was the enrolment of patients in a real-world setting, where the decision to initiate faster aspart was made independently of study participation,” the researchers said. “Accordingly, the reported outcomes provide important insights into the impact of iscCGM and faster aspart on patients in the clinic and they merit further study on a global level.”

“Overall, our findings support the treatment switch to faster aspart in combination with iscCGM in insulin-experienced patients with T1D, particularly in those in need of better glycaemic control and/or more flexible bolus administration,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).